1. Aberrant N-cadherin expression in cancer
- Author
-
Ping Leng, Zhi Wang, and Zhan-Qi Cao
- Subjects
0301 basic medicine ,Angiogenesis ,Cell Survival ,RM1-950 ,Models, Biological ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Breast cancer ,Cell Movement ,Neoplasms ,medicine ,Cell Adhesion ,Animals ,Humans ,Lung cancer ,Aberrant expression ,N-cadherin ,Cancer ,Pharmacology ,Cadherin ,business.industry ,General Medicine ,medicine.disease ,Cadherins ,Haematopoiesis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,Therapeutics. Pharmacology ,business - Abstract
Neural (N)-cadherin is a calcium-dependent single-chain transmembrane glycoprotein that mediates homotypic and heterotypic cell-cell adhesion. As an important member of the cadherin family, N-cadherin plays an important role in the developmental and functional regulation of the nervous system, brain, heart, skeletal muscles, blood vessels and hematopoietic microenvironment. However, aberrant expression of N-cadherin has been found in many cancers, such as lung cancer, breast cancer, prostate cancer and squamous cell carcinoma. It is increasingly recognized that aberrant expression of N-cadherin is closely related to aspects of malignant tumor progression in humans, such as transformation, adhesion, apoptosis, angiogenesis, invasion and metastasis, suggesting that N-cadherin can be a therapeutic target for tumor invasion and metastasis. This minireview summarizes the diverse roles of N-cadherin in cancer progression and the regulatory factors that affect the expression of N-cadherin in cancer, findings that increase our awareness of the importance of developing new therapeutic agents targeting N-cadherin.
- Published
- 2019